Recombinant CEACAM6 Monoclonal Antibody (AN302030L)
For research use only.
| Verified Samples |
Verified Samples in WB: LNCaP (negative control), A549 Verified Samples in IHC: Human spleen, Human colon cancer |
| Dilution | WB 1:1000, IHC 1:200 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, Rat, Mouse |
| Applications | WB, IHC |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Peptide. This information is proprietary to PTMab. |
| Abbre | CEACAM6 |
| Synonyms | CEACAM, CEACAM6, CD66c, CEAL, NCA, Carcinoembryonic antigen related cell adhesion molecule 6, Carcinoembryonic antigen related cell adhesion molecule 6 (non specific cross reacting antigen), Carcinoembryonic antigen-related cell adhesion molecule 6, CD 66c, CD66c antigen, CEA LIKE PROTEIN, CEACAM 6, CEAM6, MGC93832, Non specific cross reacting antigen, Non-specific crossreacting antigen, Normal cross reacting antigen, Normal cross-reacting antigen |
| Swissprot | |
| Calculated MW | 37 kDa |
| Observed MW |
40-100 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Cell Membrane |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Tags & Cell Markers, Immunology, Cancer |
| Clone No. | A750 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Carcinoembryonic antigen (CEA)-related cell adhesion molecule 6 (CEACAM6) is a member of the CEA-related cell adhesion molecule (CEACAM) family. CEACAMs bind to themselves and other family members to carry out numerous cellular functions, including proliferation, signaling, differentiation, tumor suppression, and survival. CEACAM6 is a single-chain, glycosylphosphatidylinositol (GPI)-anchored, highly glycosylated protein that is normally expressed on epithelial cells and granulocytes. CEACAM6 mediates homophilic and heterophilic cell adhesion with other CEA-related cell adhesion molecules, such as CEACAM5 and CEACAM8. Heterophilic interaction with CEACAM8 occurs in activated neutrophils, and plays a role in neutrophil adhesion to cytokine-activated endothelial cells. High levels of CEACAM6 expression are also observed in several different cancers. In cancer, CEACAM6 promotes tumor progression, migration, invasion, and metastasis, and therefore is considered a target for therapeutic intervention. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
